Trial register facet
Phase 3 trial records — page 8
351 records at phase 3.
Showing 0 records on this page
Records
351 documents · page 8 of 15
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| HARMONY-OUTCOMES | Dulaglutide | Phase 3 | Reported | Event-driven cardiovascular outcome trial | 9,463 | 2018 | Moderate |
| SUSTAIN-7-BIOMARKERprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |
| AWARD-7-REGIONAL-JPprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |
| HARMONY-OUTCOMES-BODY-COMPprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |
| SUSTAIN-7-ADHERENCEprogramme record | Semaglutide | Phase 3 | Reported | Observational | — | 2018 | Very low |
| AWARD-7-BODY-COMPprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |
| HARMONY-OUTCOMES-REGIONAL-JPprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |
| SUSTAIN-7-OLEprogramme record | Semaglutide | Phase 3 | Reported | Single-arm open-label | — | 2018 | Very low |
| AWARD-7-QOLprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |
| HARMONY-OUTCOMES-REGIONAL-CNprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |
| SUSTAIN-7-ELDERLYprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |
| AWARD-7-REGIONAL-CNprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |
| HARMONY-OUTCOMES-QOLprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |
| HARMONY-OUTCOMES-ADHERENCEprogramme record | Dulaglutide | Phase 3 | Reported | Observational | — | 2018 | Very low |
| SUSTAIN-1 | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 388 | 2017 | High |
| SCALE-PREDIABETES | Liraglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 2,254 | 2017 | Moderate |
| EXSCEL | Exenatide | Phase 3 | Reported | Event-driven cardiovascular outcome trial | 14,752 | 2017 | High |
| SUSTAIN-1-QOLprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2017 | Very low |
| SCALE-PREDIABETES-OLEprogramme record | Liraglutide | Phase 3 | Reported | Single-arm open-label | — | 2017 | Very low |
| EXSCEL-REGIONAL-CNprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2017 | Very low |
| SUSTAIN-1-REGIONAL-CNprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2017 | Very low |
| SCALE-PREDIABETES-ELDERLYprogramme record | Liraglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2017 | Very low |
| EXSCEL-QOLprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2017 | Very low |
| SUSTAIN-1-REGIONAL-JPprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2017 | Very low |
page 8 of 15